{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:00:27Z","timestamp":1781881227423,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,27]]},"DOI":"10.7759\/cureus.57066","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T20:07:56Z","timestamp":1711570076000},"source":"Crossref","is-referenced-by-count":12,"title":["Treatment Efficacy of Plasmapheresis Versus Intravenous Immunoglobulin in Guillain-Barr\u00e9 Syndrome Management: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Sanath","family":"Savithri Nandeesha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alousious","family":"Kasagga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chnoor","family":"Hawrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirubel  T","family":"Hailu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korlos","family":"Salib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar JJ","year":"2011","unstructured":"Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011, 36:123-33. 10.1159\/000324710","journal-title":"Neuroepidemiology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Yuki N","year":"2012","unstructured":"Yuki N, Hartung HP. Guillain-Barr\u00e9 syndrome. N Engl J Med. 2012, 366:2294-304. 10.1056\/NEJMra1114525","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1193006","article-title":"Guillain-Barr\u00e9 syndrome: causes, immunopathogenic mechanisms and treatment","volume":"12","author":"Jasti AK","year":"2016","unstructured":"Jasti AK, Selmi C, Sarmiento-Monroy JC, Vega DA, Anaya JM, Gershwin ME. Guillain-Barr\u00e9 syndrome: causes, immunopathogenic mechanisms and treatment. Expert Rev Clin Immunol. 2016, 12:1175-89. 10.1080\/1744666X.2016.1193006","journal-title":"Expert Rev Clin Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70215-1","article-title":"Clinical features, pathogenesis, and treatment of Guillain-Barr\u00e9 syndrome","volume":"7","author":"Van Doorn PA","year":"2008","unstructured":"Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barr\u00e9 syndrome. Lancet Neurol. 2008, 7:939-50. 10.1016\/S1474-4422(08)70215-1","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"van den Berg B","year":"2014","unstructured":"van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014, 10:469-82. 10.1038\/nrneurol.2014.121","journal-title":"Nat Rev Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain-Barr\u00e9 syndrome","volume":"27 Suppl","author":"Asbury AK","year":"1990","unstructured":"Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barr\u00e9 syndrome. Ann Neurol. 1990, 27 Suppl:S21-4. 10.1002\/ana.410270707","journal-title":"Ann Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/09638280701240326","article-title":"Motor recovery after Guillain-Barr\u00e9 syndrome in childhood","volume":"29","author":"Ortiz-Corredor F","year":"2007","unstructured":"Ortiz-Corredor F, Pe\u00f1a-Preciado M, D\u00edaz-Ru\u00edz J. Motor recovery after Guillain-Barr\u00e9 syndrome in childhood. Disabil Rehabil. 2007, 29:883-9. 10.1080\/09638280701240326","journal-title":"Disabil Rehabil"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-010-9407-4","article-title":"IVIG treatment and prognosis in Guillain-Barr\u00e9 syndrome","volume":"30 Suppl 1","author":"van Doorn PA","year":"2010","unstructured":"van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC. IVIG treatment and prognosis in Guillain-Barr\u00e9 syndrome. J Clin Immunol. 2010, 30 Suppl 1:S74-8. 10.1007\/s10875-010-9407-4","journal-title":"J Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/0883073810370481","article-title":"A clinical picture of Guillain-Barr\u00e9 syndrome in children in the United States","volume":"25","author":"Hicks CW","year":"2010","unstructured":"Hicks CW, Kay B, Worley SE, Moodley M. A clinical picture of Guillain-Barr\u00e9 syndrome in children in the United States. J Child Neurol. 2010, 25:1504-10. 10.1177\/0883073810370481","journal-title":"J Child Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref11","unstructured":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. (2011). Accessed. 12\/01\/23: http:\/\/www.evidencebasedpublichealth.de\/download\/Newcastle_Ottowa_Scale_Pope_Bruce.pdf."},{"key":"ref12","unstructured":"Joanna Briggs Institute-Checklist for systematic reviews and research syntheses. (2017). Accessed. 12\/01\/23: https:\/\/joannabriggs.org\/ebp\/critical_appraisal_tools."},{"key":"ref13","unstructured":"Critical Appraisal Skills Programme (2023). CASP (Randomised Controlled Trial ) Checklist. (2023). Accessed. 12\/01\/23: https:\/\/casp-uk.net\/checklists\/casp-rct-randomised-controlled-trial-checklist.docx."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2014.18.35.2911","article-title":"Intravenous immunoglobulin vs plasma exchange in treatment of mechanically ventilated adults with Guillain-Barr\u00e9 syndrome","volume":"18","author":"Charra B","year":"2014","unstructured":"Charra B, Hachimi A, Benslama A, Motaouakkil S. Intravenous immunoglobulin vs plasma exchange in treatment of mechanically ventilated adults with Guillain-Barr\u00e9 syndrome. Pan Afr Med J. 2014, 18:35. 10.11604\/pamj.2014.18.35.2911","journal-title":"Pan Afr Med J"},{"key":"ref15","article-title":"Comparison of effectiveness and unit cost of intravenous immunoglobulin (IVIG) and plasma exchange (PE) in therapy for Guillain-Barr\u00e9 syndrome in Ratchaburi hospital","volume":"33","author":"Rodprasert K","year":"2018","unstructured":"Rodprasert K. Comparison of effectiveness and unit cost of intravenous immunoglobulin (IVIG) and plasma exchange (PE) in therapy for Guillain-Barr\u00e9 syndrome in Ratchaburi hospital. Reg 4-5 Med J. 2018, 33:157-63.","journal-title":"Reg 4-5 Med J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/1756285615610471","article-title":"A comparison between plasmapheresis and intravenous immunoglobulin in children with Guillain-Barr\u00e9 syndrome in Upper Egypt","volume":"9","author":"Saad K","year":"2016","unstructured":"Saad K, Mohamad IL, Abd El-Hamed MA, et al.. A comparison between plasmapheresis and intravenous immunoglobulin in children with Guillain-Barr\u00e9 syndrome in Upper Egypt. Ther Adv Neurol Disord. 2016, 9:3-8. 10.1177\/1756285615610471","journal-title":"Ther Adv Neurol Disord"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/cc10305","article-title":"Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barr\u00e9 syndrome: a randomized study","volume":"15","author":"El-Bayoumi MA","year":"2011","unstructured":"El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barr\u00e9 syndrome: a randomized study. Crit Care. 2011, 15:R164. 10.1186\/cc10305","journal-title":"Crit Care"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3329\/jninb.v5i2.43015","article-title":"Comparison of ICU outcomes between intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated patients with GuillainBarr\u00e9 syndrome in a neuro-intensive care unit in a Govt. Hospital of Bangladesh: a observational cohort study","volume":"5","author":"Mallick UK","year":"2019","unstructured":"Mallick UK, Chowdhury MSJH, Hussain ME, et al.. Comparison of ICU outcomes between intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated patients with GuillainBarr\u00e9 syndrome in a neuro-intensive care unit in a Govt. Hospital of Bangladesh: a observational cohort study. J Natl Inst Neurosci Bangladesh. 2019, 5:118-22. 10.3329\/jninb.v5i2.43015","journal-title":"J Natl Inst Neurosci Bangladesh"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26831","article-title":"Nationwide study of therapeutic plasma exchange vs intravenous immunoglobulin in Guillain-Barr\u00e9 syndrome","volume":"61","author":"Beydoun HA","year":"2020","unstructured":"Beydoun HA, Beydoun MA, Hossain S, Zonderman AB, Eid SM. Nationwide study of therapeutic plasma exchange vs intravenous immunoglobulin in Guillain-Barr\u00e9 syndrome. Muscle Nerve. 2020, 61:608-15. 10.1002\/mus.26831","journal-title":"Muscle Nerve"},{"key":"ref20","article-title":"Intravenous immune globulin vs plasma exchange in Guillain barre syndrome a 5-year retrospective study","author":"Ashalatha R","year":"2002","unstructured":"Ashalatha R. Intravenous immune globulin vs plasma exchange in Guillain barre syndrome a 5-year retrospective study. Radhakrishnan K (ed): Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Trivandrum; 2002."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2014.890859","article-title":"Management of Guillain-Barr\u00e9 syndrome with plasmapheresis or immunoglobulin: our experience from a tertiary care institute in South India","volume":"36","author":"Kishore CK","year":"2014","unstructured":"Kishore CK, Vijayabhaskar J, Vishnu Vardhan R, et al.. Management of Guillain-Barr\u00e9 syndrome with plasmapheresis or immunoglobulin: our experience from a tertiary care institute in South India. Ren Fail. 2014, 36:732-6. 10.3109\/0886022X.2014.890859","journal-title":"Ren Fail"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/BF02229327","article-title":"High dose intravenous immune globulins and plasma exchange in Guillain-Barr\u00e9 syndrome","volume":"16","author":"Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology Italy","year":"1995","unstructured":"Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology Italy, Participating Centers, Ravasio A, et al.. High dose intravenous immune globulins and plasma exchange in Guillain-Barr\u00e9 syndrome. Ital J Neurol Sci. 1995, 16:487-92. 10.1007\/BF02229327","journal-title":"Ital J Neurol Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3205\/000220","article-title":"Guillain-Barr\u00e9 syndrome: clinical profile and management","volume":"13","author":"Sudulagunta SR","year":"2015","unstructured":"Sudulagunta SR, Sodalagunta MB, Sepehrar M, et al.. Guillain-Barr\u00e9 syndrome: clinical profile and management. Ger Med Sci. 2015, 13:Doc16. 10.3205\/000220","journal-title":"Ger Med Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome","volume":"349","author":"Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group","year":"1997","unstructured":"Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome. Lancet. 1997, 349:225-30. 10.1016\/S0140-6736(96)09095-2","journal-title":"Lancet"},{"key":"ref25","article-title":"Outcome of various treatments in Guillain-Barr\u00e9 Syndrome in Children","volume":"14","author":"Anwer J","year":"2020","unstructured":"Anwer J, Khalid S, Haq R, Iqbal R, Mahmood Z, Tayyab H. Outcome of various treatments in Guillain-Barr\u00e9 Syndrome in Children. Pak J Med Sci . 2020, 14:296-8.","journal-title":"Pak J Med Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4598(200101)24:1%3C54::AID-MUS6%3E3.0.CO;2-9","article-title":"Intravenous immunoglobulin therapy for Guillain-Barr\u00e9 syndrome with IgG anti-GM1 antibody","volume":"24","author":"Kuwabara S","year":"2001","unstructured":"Kuwabara S, Mori M, Ogawara K, et al.. Intravenous immunoglobulin therapy for Guillain-Barr\u00e9 syndrome with IgG anti-GM1 antibody. Muscle Nerve. 2001, 24:54-8. 10.1002\/1097-4598(200101)24:1%3C54::AID-MUS6%3E3.0.CO;2-9","journal-title":"Muscle Nerve"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12169","article-title":"Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian-Barre syndrome","volume":"25","author":"Ye Y","year":"2015","unstructured":"Ye Y, Li SL, Li YJ. Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian-Barre syndrome. Transfus Med. 2015, 25:79-84. 10.1111\/tme.12169","journal-title":"Transfus Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.36570\/jduhs.2019.3.693","article-title":"Plasma exchange versus intravenous immunoglobulin in children with Guillain Barr\u00e9 syndrome","volume":"13","author":"Elahi E","year":"2019","unstructured":"Elahi E, Ashfaq M, Nisa BU, Chachar S. Plasma exchange versus intravenous immunoglobulin in children with Guillain Barr\u00e9 syndrome. J Dow Univ Health Sci. 2019, 13:133-7. 10.36570\/jduhs.2019.3.693","journal-title":"J Dow Univ Health Sci"},{"key":"ref29","article-title":"Plasmapheresis versus intravenous immunoglobulins in guillain barre syndrome, the therapeutic outcomes","volume":"65","author":"Asghar SP","year":"2015","unstructured":"Asghar SP, Mubarik H, Shams N, Cheema MB, Shah S. Plasmapheresis versus intravenous immunoglobulins in guillain barre syndrome, the therapeutic outcomes. Pak Armed Forces Med J. 2015, 65:524-9.","journal-title":"Pak Armed Forces Med J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00e9 syndrome","volume":"326","author":"van der Mech\u00e9 FG","year":"1992","unstructured":"van der Mech\u00e9 FG, Schmitz PI, the Dutch Guillain-Barr\u00e9 Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00e9 syndrome. N Engl J Med. 1992, 326:1123-9. 10.1056\/NEJM199204233261705","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.35.8.1096","article-title":"Plasmapheresis and acute Guillain\u2010Barr\u00e9 syndrome","volume":"35","author":"The Guillain-Barre\u0301 Syndrome Study Group","year":"1985","unstructured":"The Guillain-Barre\u0301 Syndrome Study Group. Plasmapheresis and acute Guillain\u2010Barr\u00e9 syndrome. Neurology. 1985, 35:1096. 10.1212\/WNL.35.8.1096","journal-title":"Neurology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.38.10.1639","article-title":"Treatment of Guillain-Barr\u00e9 syndrome with high-dose gammaglobulin","volume":"38","author":"Kleyweg RP","year":"1988","unstructured":"Kleyweg RP, van der Mech\u00e9 FG, Meulstee J. Treatment of Guillain-Barr\u00e9 syndrome with high-dose gammaglobulin. Neurology. 1988, 38:1639-41. 10.1212\/wnl.38.10.1639","journal-title":"Neurology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm004","article-title":"Immunotherapy for Guillain-Barr\u00e9 syndrome: a systematic review","volume":"130","author":"Hughes RA","year":"2007","unstructured":"Hughes RA, Swan AV, Rapha\u00ebl JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barr\u00e9 syndrome: a systematic review. Brain. 2007, 130:2245-57. 10.1093\/brain\/awm004","journal-title":"Brain"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92644-2","article-title":"Controlled trial of prednisolone in acute polyneuropathy","volume":"7","author":"Hughes RA","year":"1978","unstructured":"Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet. 1978, 7:750-3. 10.1016\/S0140-6736(78)92644-2","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002063.pub6","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","volume":"2014","author":"Hughes RA","year":"2014","unstructured":"Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev. 2014, 2014:CD002063. 10.1002\/14651858.CD002063.pub6","journal-title":"Cochrane Database Syst Rev"},{"key":"ref36","article-title":"Current therapeutic options in severe Guillain-Barre syndrome","volume":"29","author":"Shahar E","year":"2001","unstructured":"Shahar E. Current therapeutic options in severe Guillain-Barre syndrome. Clin Neuropharmacol. 2001, 29:45-51.","journal-title":"Clin Neuropharmacol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-11-101","article-title":"Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barr\u00e9 syndrome","volume":"11","author":"Winters JL","year":"2011","unstructured":"Winters JL, Brown D, Hazard E, Chainani A, Andrzejewski C Jr. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barr\u00e9 syndrome. BMC Health Serv Res. 2011, 11:101. 10.1186\/1472-6963-11-101","journal-title":"BMC Health Serv Res"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2023.100468","article-title":"Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barr\u00e9 syndrome (GBS) in patients with severe symptoms: a systematic review and meta-analysis","volume":"31","author":"Zaki HA","year":"2023","unstructured":"Zaki HA, Iftikhar H, Najam M, et al.. Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barr\u00e9 syndrome (GBS) in patients with severe symptoms: a systematic review and meta-analysis. eNeurologicalSci. 2023, 31:100468. 10.1016\/j.ensci.2023.100468","journal-title":"eNeurologicalSci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/222529-treatment-efficacy-of-plasmapheresis-versus-intravenous-immunoglobulin-in-guillain-barr-syndrome-management-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T20:08:04Z","timestamp":1711570084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/222529-treatment-efficacy-of-plasmapheresis-versus-intravenous-immunoglobulin-in-guillain-barr-syndrome-management-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.57066","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,27]]}}}